Guardant Health in the U.S.: Cancer Blood Tests, Business, and What It Means for You

By /

Most articles you find about Guardant Health talk about one thing: the stock.
Who bought. Who sold. Why the share price moved today.

That kind of news can matter if you own the stock.
But it barely explains what Guardant actually does, how its tests help real people, or what to watch if you’re thinking about your health or your money.

This guide focuses on what most stock‑focused pieces miss:

  • What Guardant Health really is and how its cancer blood tests work
  • How those tests are used in U.S. hospitals and clinics
  • What patients, families, doctors, and investors should know
  • How to think about scary headlines like “big investor cuts stake”

Table of Contents

What is Guardant Health?

Guardant Health is a U.S. diagnostics company that makes blood tests to detect and track cancer.

  • Headquarters: Redwood City, California
  • Ticker symbol: GH (Nasdaq)
  • Main focus: “Liquid biopsy” blood tests that find tiny bits of tumor DNA in the bloodstream
  • Customers: Oncologists, hospitals, health systems, drug companies, and, increasingly, people doing cancer screening

In simple terms: Guardant tries to replace or reduce painful tissue biopsies and some other invasive tests with a tube of blood.

Quick facts about Guardant Health (U.S. context)

  • Founded: 2012
  • Founders: Helmy Eltoukhy and AmirAli Talasaz
  • Core technology: Next‑generation sequencing (NGS) of circulating tumor DNA (ctDNA)
  • Flagship tests: Guardant360, Guardant Reveal, Shield
  • Main areas:
    • Advanced cancer profiling (helping pick the right drug)
    • Monitoring for recurrence or treatment response
    • Colorectal cancer screening for average‑risk adults

How Guardant’s cancer blood tests work (in plain language)

Liquid biopsy vs. traditional biopsy

A traditional biopsy means a surgeon or radiologist takes a piece of a tumor with a needle or during surgery.
That sample is then sent to a lab.

A liquid biopsy uses a blood sample instead. Guardant’s labs look for bits of tumor DNA that tumors shed into the bloodstream.

Why doctors care about liquid biopsy

Compared with a tissue biopsy, a blood test can be:

  • Less invasive and less painful
  • Faster to do and process
  • Possible even when the tumor is hard to reach
  • Able to capture DNA from multiple tumor sites, not just one spot

But it also has limits:

  • If a tumor is very small or not shedding much DNA, the test can miss it
  • It doesn’t replace all tissue biopsies; many patients still need at least one tissue sample

What Guardant’s labs actually look for

In the blood, Guardant’s tests look for:

  • Small pieces of DNA from cancer cells (ctDNA)
  • Specific gene changes (mutations, fusions, amplifications) linked to:
    • Certain cancer types
    • Response or resistance to specific drugs

By mapping those DNA changes, doctors can often:

  • Confirm the cancer has certain “targets”
  • Choose a targeted therapy or immunotherapy
  • See if a treatment is working or if resistance is building

The main Guardant Health tests in the U.S.

1. Guardant360: for people with advanced cancer

What it is
Guardant360 is a blood test used mainly in people with advanced or metastatic solid tumors (like lung, colon, breast, prostate, and others).

What it does

  • Looks at many cancer‑related genes in one test
  • Finds mutations, fusions, and other changes
  • Helps match the patient to:
    • FDA‑approved targeted drugs
    • Clinical trials

How it’s used in real life

Example:
Someone is diagnosed with advanced non‑small cell lung cancer.

Instead of waiting for a tissue biopsy and genetic testing (which can take time and may be hard to do), the oncologist can order Guardant360:

  • A nurse draws blood
  • The tube goes to Guardant’s lab
  • The doctor gets a report listing key mutations and potential therapies

That report can help decide whether to use:

  • Targeted pills (for certain EGFR, ALK, ROS1, KRAS, etc. mutations)
  • Immunotherapy
  • Standard chemotherapy

2. Guardant360 CDx: companion diagnostic

Guardant360 CDx is an FDA‑approved version of Guardant360 that acts as a “companion diagnostic” for specific cancer drugs.

That means:

  • For some drugs, the drug label and FDA specify that Guardant360 CDx is an approved way to test if a patient is eligible
  • This strengthens Guardant’s role in precision oncology and can support insurance coverage

3. Guardant Reveal: checking for leftover cancer

Guardant Reveal focuses on minimal residual disease (MRD) — tiny amounts of cancer left in the body after treatment that are too small to see on scans.

It’s used mainly in early‑stage colorectal cancer (and some other solid tumors) to:

  • Check after surgery or treatment if cancer DNA is still in the blood
  • Monitor over time for signs of recurrence

If the test shows ctDNA:

  • It may mean cancer cells are still present
  • Oncologists can consider more aggressive treatment or closer monitoring

If no ctDNA is found:

  • Doctors may be more comfortable with less treatment or standard follow‑up
  • It may spare some people unnecessary chemotherapy

4. Shield: a blood test for colorectal cancer screening

Shield is Guardant’s blood‑based test for colorectal cancer screening in average‑risk adults.

Who it’s aimed at

  • Adults 45 and older at average risk of colorectal cancer
  • People who are candidates for colonoscopy but:
    • Don’t want it
    • Can’t get it easily (logistics, access, medical reasons)
    • Refuse or delay stool‑based tests

How it works

  • One standard blood draw
  • The lab looks for ctDNA patterns linked to colorectal cancer
  • The result helps flag whether a colonoscopy is needed

How it compares to other options (in broad terms)

  • Pros
    • Much simpler than colonoscopy
    • No bowel prep, sedation, or time off work
    • No stool handling, unlike stool tests
  • Cons / limits
    • A positive result still means you need a colonoscopy
    • It does not catch every cancer or every pre‑cancerous polyp
    • It does not yet fully replace colonoscopy in U.S. screening guidelines

As of 2024, Shield has been offered as a lab‑developed test while Guardant works with regulators on formal FDA approval.
Coverage and guideline status are evolving, so it’s important to:

  • Check the latest FDA updates
  • Ask your doctor and your insurer what’s covered right now

5. Other Guardant tests (briefly)

Guardant also offers other tests and services, mainly for specialists and drug companies:

  • Guardant TissueNext: tissue‑based genomic profiling when tumor tissue is available
  • GuardantOMNI / GuardantINFINITY: broader genomic panels often used in research and drug development
  • Services for pharmaceutical companies:
    • Helping design and run clinical trials
    • Finding trial patients with specific mutations
    • Developing companion diagnostics for new drugs

Why Guardant Health matters for cancer care in the U.S.

Making precision medicine more accessible

Not every hospital has advanced genomic labs.
Not every patient can safely undergo a tissue biopsy.

Guardant’s blood tests help:

  • Community oncologists order cutting‑edge genomic testing without shipping tumor tissue
  • Patients in smaller towns access testing that used to be limited to major academic centers

Reducing the burden of invasive procedures

Liquid biopsy can be especially helpful when:

  • Tissue is hard to reach (e.g., deep lung lesions, some liver tumors)
  • A patient is too frail for an invasive procedure
  • A doctor needs repeat testing to track resistance over time

Helping match patients to the right drugs

When cancer DNA is profiled, doctors can:

  • Avoid drugs that are unlikely to help
  • Focus on therapies targeted to the tumor’s actual mutations
  • Find clinical trials that match a patient’s specific profile

This can:

  • Improve outcomes for some patients
  • Avoid wasted time on ineffective treatments
  • Potentially reduce side effects and costs from mismatched therapies

Important limitations

Guardant’s tests are powerful but not magic. They:

  • Can miss cancers that shed very little DNA into the blood
  • Cannot fully replace imaging, pathology, and expert clinical judgment
  • Sometimes still require confirmation with tissue biopsy

For any individual case, a doctor needs to weigh:

  • The benefits of more information from a blood test
  • The risks of false negatives or unclear findings
  • The costs and coverage for that specific patient

Guardant Health as a business and stock (GH)

Many people come to Guardant through investing apps or stock news.
Understanding the business model helps you make sense of those headlines.

How Guardant makes money

Guardant has three main revenue streams:

  1. Clinical testing for patients
    • Tests ordered by U.S. oncologists, gastroenterologists, surgeons, and primary care doctors
    • Billed to:
      • Medicare and Medicaid
      • Commercial insurers
      • Hospital systems
      • Sometimes directly to patients
  2. Biopharma partnerships
    • Drug companies pay Guardant to:
      • Use its tests in clinical trials
      • Help find patients with specific mutations
      • Develop companion diagnostics for new drugs
  3. Screening
    • Blood‑based CRC screening (Shield) for average‑risk adults
    • This market is early, but very large if adoption grows

Market opportunity in the U.S.

Areas where Guardant is active:

  • Advanced cancer genomics
    • Hundreds of thousands of U.S. patients each year with advanced solid tumors could be candidates for genomic profiling
  • Minimal residual disease (MRD) and recurrence monitoring
    • Millions of people living after cancer surgery could, in time, be candidates for blood‑based MRD tests
  • Colorectal cancer screening
    • Tens of millions of U.S. adults are eligible for CRC screening
    • Many avoid colonoscopy or stool tests
    • A simple blood test could reach some of these people

Because of this, investors often see Guardant as a high‑growth, high‑risk play on the future of cancer testing.

Financial picture (big picture, not price targets)

As of 2024:

  • Revenue has been growing, driven by:
    • More Guardant360 use
    • MRD and screening expansion
    • Biopharma deals
  • The company has not yet been consistently profitable
    • Very high spending on R&D, sales, and marketing
    • Building data, clinical trials, and infrastructure
  • The stock has been volatile
    • Moves with:
      • Trial results
      • Reimbursement decisions
      • General biotech sentiment
      • Big moves by institutional investors

Always check the latest quarterly reports and 10‑K filings for up‑to‑date numbers.

Key competitors in the U.S.

Guardant is part of a crowded field:

  • Exact Sciences (Cologuard, Oncotype tests)
  • Foundation Medicine (owned by Roche)
  • Natera (Signatera MRD test)
  • Grail (Galleri multi‑cancer early detection)
  • Major diagnostic labs and local hospital labs

Each competitor has its own strengths:

  • Exact Sciences dominates stool‑based CRC screening
  • Natera has strong traction in MRD for certain cancers
  • Foundation Medicine has deep tissue‑based profiling

Guardant’s edge is its focus and experience in liquid biopsy and its growing clinical and real‑world data.

Main risks investors should understand

Owning or considering GH stock? Core risks include:

  • Reimbursement risk
    • Medicare and commercial payers must agree to cover tests
    • Coverage policies can change
  • Regulatory risk
    • FDA views on lab‑developed tests and screening tests can shift
    • Shield’s approval and labeling will matter a lot
  • Clinical data risk
    • Tests must continue to show strong performance in large trials
    • Poor results could damage adoption
  • Competition
    • Other companies may launch similar or better tests
    • Hospitals may build in‑house solutions
  • Cash burn and dilution
    • If spending stays high and profits are far off, Guardant may issue more shares or take on debt

What to watch if you’re evaluating GH stock

This isn’t investment advice, but common focal points include:

  • Test volume growth
    • How fast are oncologists, surgeons, and primary care doctors ordering Guardant tests?
  • Segment breakdown
    • Growth in:
      • Advanced cancer testing
      • MRD / recurrence monitoring
      • Screening (Shield)
  • Gross margin and operating loss
    • Are margins improving as volume scales?
    • Is the company moving toward breakeven?
  • Cash position and runway
    • Enough cash to fund R&D and commercialization for several years?
  • Regulatory and guideline updates
    • FDA decisions on Shield and other tests
    • Inclusion in major guidelines (NCCN, USPSTF, etc.)
    • New Medicare or private payer coverage decisions
  • New clinical data
    • Results of large trials like those validating Shield and MRD tests
    • Data presented at major oncology meetings

Discuss any investment decision with a licensed financial advisor who understands your goals and risk tolerance.

Making sense of headlines about big investors selling Guardant Health

Competitor articles often look like this:

  • “Large fund cuts Guardant Health stake”
  • “Insider sells X shares of GH”

These headlines get clicks, but here’s what they do not tell you: whether Guardant’s science, products, and long‑term story are better or worse.

What “big investor sold shares” can actually mean

Institutional investors (mutual funds, pension funds, hedge funds) file regular reports showing their holdings.
Changes can happen for many reasons:

  • Portfolio rebalancing
  • Taking profits or tax‑loss harvesting
  • Shifting from one sector to another
  • Internal risk limits on position size
  • A change in their own investment thesis

Sometimes selling signals concern. Other times, it’s just housekeeping.

Insider selling: should you panic?

Executives and directors often have pre‑scheduled selling plans (Rule 10b5‑1 plans).
Reasons they might sell:

  • Diversifying their personal finances
  • Paying taxes
  • Life events (home purchase, education, etc.)

A single insider sale does not automatically mean “the company is in trouble.”
Stronger warning signs might be:

  • Many insiders selling large amounts all at once
  • Selling right before clearly negative news (and even then, regulators may get involved)

How to react as a retail investor

Instead of reacting only to who sold:

  1. Look at why you own or are considering the stock
    • Do you believe in the science and long‑term need for liquid biopsies?
    • Do you understand the risks?
  2. Check the fundamentals
    • Revenue growth, margins, cash, trial results, regulatory milestones
  3. Consider overall portfolio risk
    • Biotech is volatile
    • Make sure your position size fits your risk tolerance
  4. Use big investor moves as data points, not as your entire thesis

For U.S. patients: how to access a Guardant test

Who might benefit from Guardant360

You might ask your oncologist about Guardant360 if you:

  • Have an advanced or metastatic solid tumor (like lung, colon, breast, prostate, bladder, or others)
  • Have limited or risky options for a tissue biopsy
  • Need rapid information on whether targeted therapies are an option
  • Have disease progression and your doctor wants to see if new resistance mutations have appeared

Only your oncology team can decide if it fits your case, but you can bring it up.

How to talk with your oncologist

You can ask:

  • “Would a liquid biopsy like Guardant360 give us more information about my cancer?”
  • “Do I still need a tissue biopsy, or could a blood test be enough for now?”
  • “How would the results change our treatment plan?”
  • “Is it covered by my insurance or Medicare in my situation?”

Doctors who use these tests regularly can usually explain:

  • Why they recommend them
  • What they expect to learn
  • What they would do with each possible result

Insurance coverage and cost in the U.S.

Coverage varies by test and indication, but as a general guide:

  • Medicare
    • Often covers Guardant360 for appropriate advanced solid tumor cases
    • Coverage criteria are specific; your doctor’s office and Guardant’s billing team can check
  • Commercial insurance
    • Policies differ by plan and state
    • Many major insurers cover liquid biopsy for certain cancers
  • Out‑of‑pocket cost
    • Depends on deductibles, coinsurance, and network status
    • Guardant typically has patient assistance programs:
      • They may cap costs for eligible patients
      • They can help appeal denials

If cost is a concern, ask:

  • “Can your office or Guardant’s patient support check my benefits before we order the test?”
  • “Are there financial assistance programs if my insurance does not cover it fully?”

Using Shield for colorectal cancer screening

If you’re 45 or older and at average risk of colorectal cancer, you can ask your doctor:

  • “Am I up to date on colorectal cancer screening?”
  • “What options do I have — colonoscopy, stool tests, or blood tests like Shield?”
  • “Given my risk and preferences, what do you recommend?”

Be aware:

  • A positive Shield (or any non‑colonoscopy) test usually leads to a diagnostic colonoscopy
  • Colonoscopy remains the gold standard for:
    • Finding and removing polyps
    • Direct visualization of the colon

The best screening test is often the one you are willing and able to complete on schedule.

Guardant’s future: what to watch beyond the next quarter

Moving into earlier detection

Guardant and other companies are pushing toward:

  • Detecting cancer earlier in otherwise healthy people
  • Screening more cancer types with a single blood draw

This is a big opportunity, but also very challenging:

  • Tests must be accurate enough to avoid too many false positives
  • Regulators and guideline bodies are cautious

Better monitoring over time

Expect continued work on:

  • MRD tests for more tumor types
  • Using ctDNA levels to:
    • Adjust treatment intensity
    • Decide when to stop or switch therapies

Data, AI, and large genomic databases

Guardant’s growing datasets on:

  • Tumor DNA changes
  • Treatment choices
  • Outcomes over time

…can feed advanced analytics and AI models.
The goal is to:

  • Spot patterns humans might miss
  • Predict which treatments will work best for which types of tumors

This data advantage could be a major long‑term asset if handled responsibly and securely.

Practical tips

If you’re a patient or caregiver in the U.S.

  • Ask your oncologist whether a liquid biopsy is appropriate in your case
  • If you’re 45+ and not up to date on colorectal screening, ask about all options:
    • Colonoscopy
    • Stool tests
    • Blood tests like Shield (if available and appropriate)
  • Always ask:
    • “What will we do differently based on this test result?”
    • “How much will it cost me, and who can help check coverage?”

If you’re considering GH as an investment

  • Treat Guardant as a high‑risk, high‑potential biotech, not a bond substitute
  • Build your view around:
    • Clinical value of its tests
    • Adoption trends by doctors and health systems
    • Regulatory and coverage milestones
  • Diversify. A single stock, especially in biotech, should rarely dominate your portfolio
  • Discuss your plan with a qualified financial advisor

If you’re a clinician

  • Stay current on:
    • NCCN and other guideline updates on liquid biopsy
    • Payer coverage policies in your state
    • New data from major oncology meetings
  • Work with your institution’s lab, billing team, and patient navigators to integrate these tests smoothly and transparently.

Conclusion

Guardant Health is more than a volatile ticker symbol.

At its core, it’s a U.S. diagnostics company trying to make cancer testing:

  • Less invasive
  • More precise
  • Easier to access for patients and doctors

For patients, that can mean fewer painful procedures and faster answers.
For doctors, it can mean better tools to match the right person to the right therapy at the right time.
For investors, it’s a bet that liquid biopsy and blood‑based screening will take a growing share of cancer care.

Headlines about big funds buying or selling GH come and go.
What matters more is whether Guardant’s tests keep proving themselves in clinics, trials, and real‑world outcomes.

FAQs about Guardant Health (U.S.)

1. What does Guardant Health do in simple terms?
Guardant Health makes blood tests that look for cancer DNA in your blood. These tests help doctors find, track, and choose treatments for cancer without always needing a tissue biopsy.

2. Is Guardant’s Shield test a replacement for colonoscopy?
Not completely. Shield is a blood test that can help screen for colorectal cancer, but a positive result still requires a colonoscopy. Colonoscopy remains the gold standard and the only test that can both find and remove most polyps.

3. How accurate are Guardant’s cancer blood tests?
Accuracy varies by test and use case. Guardant’s tests have shown strong performance in clinical trials, but no test is perfect. Some cancers won’t shed enough DNA to be detected, and some early lesions may be missed. Your doctor can explain accuracy in your specific situation.

4. Does Medicare cover Guardant360 and Shield?
Medicare generally covers Guardant360 for many patients with advanced solid tumors when ordered appropriately. Coverage for Shield is more limited and evolving. Always have your doctor’s office and Guardant’s support team check your specific coverage

5. How much does a Guardant360 test cost in the U.S.?
The list price can be high, but most insured patients don’t pay that amount. Out‑of‑pocket cost depends on your insurance plan, deductible, and network status. Guardant offers financial assistance and can help estimate your cost before testing.

6. Is Guardant Health profitable?
As of 2024, Guardant Health has been growing revenue but has not yet achieved consistent profitability. The company spends heavily on research, clinical trials, and commercialization.

7. Is GH stock very risky?
Yes. Like many biotech stocks, GH is volatile and carries significant risk. Its future depends on scientific results, regulatory decisions, competition, and reimbursement. Only invest money you can afford to risk and consider professional advice.

8. Who owns Guardant Health?
Guardant is a publicly traded company. Ownership is split among institutional investors (mutual funds, hedge funds, pension funds), insiders (founders and executives), and individual investors who own GH shares.

9. How do I know if a Guardant test is right for me?
Talk to your doctor. Share your diagnosis, stage, prior tests, and concerns. Ask whether a liquid biopsy or Shield fits your case and how the result would change your care.

10. Where is Guardant Health based?
Guardant Health is headquartered in Redwood City, California, and operates CLIA‑certified laboratories in the United States to run its tests.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top